From: A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
Cohort
# Evaluable Subjects
Capecitabine
P.O. (mg/m2)
BID, Days 1–14
Ziv-Aflibercept
I.V. (mg/kg)
Q3 weeks, Day 1
Phase Ib (dose escalation)
 Cohort 1
7
850
6
 Cohort 2
1000
Phase II (expansion)
50